Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

H2-antagonists face supply disruption

The Department of Health and Social Care (DH) has issued supply notification for various strengths of three H2-antagonists- Cimetidine, Famotidine, and Nizatidine.

ProductSupplierAnticipated Resupply dateDetail
Famotidine 20mg tabletsTilomed LaboratoriesOut of stock, resupply mid October 2020
Teva UKOut of stock, resupply w/c 5th October 2020
Famotidine 40mg tabletsTilomed LaboratoriesIn stock
Teva UKOut of stock, resupply w/c 5th October 2020
Cimetidine 200mg tabletsEnnogen PharmaJune 2021Unlicensed supplies have been sourced
Medreichto be confirmed
Cimetidine 400mg tabletsEnnogen PharmaJune 2021
Medreichto be confirmed
Cimetidine 800mg tabletsEnnogen PharmaJune 2021
Medreichto be confirmed
Cimetidine 200mg/5ml oral solutionRosemont Pharmaceuticalsn/aIn stock
Nizatidine 150mg tabletsMylanOut of stock, resupply December 2020
Medreichto be confirmed
RelonchemIn stock
Nizatidine 300mg tablets MylanOut of stock, resupply December 2020
Medreichto be confirmed
RelonchemIn stock

The following specialist importers have confirmed that they can source unlicensed Cimetidine tablets.


  • Alium Medical (200mg, 400mg and 800mg)
  • Mawdsley’s Unlicensed (400mg)

There is currently no listing on dm+d for the imported product for prescribers to select using their prescribing systems so an EPS prescription for unlicensed Cimetidine (strength) tablets cannot be issued.

If a prescriber wishes to prescribe an unlicensed import, an FP10 paper prescription should be issued as ‘Cimetidine (strength) tablets (Special Order)‘ and endorsed by the pharmacy as a non-Part VIIIB special.